IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
sales and fund ing the ma jor ity of the re main ing de vel op ment ac tiv i ties. Lundbeck will re ceive a share of
the rev e nue gen er ated in the USA and Ja pan as well as roy alty pay ments on Takeda’s share of revenues.
Takeda considers that this alliance will enhance its core CNS franchise.
TAK 428 is a treat ment for di a betic neu rop a thy, in phase II tri als in Eu rope and the USA in 2009. De vel -
oped in-house, it is an enhancer of neu ral growth.
TAK 583, for the po ten tial treat ment of postherpetic neu ral gia (PHN). In 2008 it was re ported to be in
phase II stud ies in the US, Ja pan and Eu rope for pain ful di a betic neu rop a thy (PDN) and di a betic pe riph -
eral neu rop a thy (DPN) and in the US and Eu rope for postherpatic neuralgia (PHN).
TAK 065, a neuroregeneration enhancer, was in phase I tri als with Takeda in 2009 for the treat ment of
Alz hei mer’s and Par kin son’s dis ease.
Genitourinary System/Sex Hormones
asoprisnil J 867 G2X9 III
urinary incontinence therapy TAK 363, TRK 130 G4D I
SARM LGD 2226 G3B, M5B Preclinical
ASOPRISNIL (J 867), a pro ges ter one re cep tor mod u la tor is be ing de vel oped by TAP for the treat ment of
endometriosis, fib roids and hor mone de fi ciency. It is an orally ac tive SPRM (se lec tive pro ges ter one re -
cep tor mod u la tor). It could be the first SPRM to be in tro duced for core gynecological applications.
In 2003, TAP be gan phase III tri als of asoprisnil in the USA for the treat ment of fib roids and these had
com pleted and were be ing eval u ated in June 2005. In 2004, Schering AG (Ger many) was con duct ing
phase III tri als with asoprisnil, a treat ment of myomas, which are be nign tu mors of the uter ine mus cle.
Schering AG an nounced in Feb ru ary 2005 that pre lim i nary re sults from a phase III trial in pa tients with
dys func tional bleed ing as so ci ated with fib roids and myomas, showed that the agent re duced tu mor size.
Schering AG an tic i pates reg u la tory fil ings for the pro ges ter one re cep tor mod u la tor dur ing 2006. Phase II
tri als are on go ing in the USA for the treatment of endometriosis.
The TAP jv con cluded in May 2008.
Li cens ing: Asoprisnil was orig i nally de vel oped by Schering AG’s Jenapharm sub sid iary. Jenapharm li -
censed the US rights to TAP prior to 1996, when it was ac quired by Schering AG, which re ceives roy al ties
on fu ture sales of the agent.
TAK 363/TRK 130, a com pound for the po ten tial treat ment of uri nary in con ti nence/over ac tive blad der,
is in joint de vel op ment with Takeda and Toray (Ja pan). Phase I tri als in the US were ini ti ated in 2007 and
ongoing in 2009.
Li cens ing: In April 2005, the com pa nies an nounced that they had signed an agree ment to co-de velop
the com pound. Toray will mar ket the agent in Ja pan, and Takeda will mar ket the com pound in over seas
ter ri to ries. The com pound was dis cov ered in Toray’s com pound li brary through joint re search by both
companies.
Com pe ti tion: Over ac tive blad der symp toms are now mostly treated with anticholinergics and newer
agents such as Astellas’ (Ja pan) Vesicare (solfenacin) and Novartis’ (Swit zer land) Enablex
(darifenacin) which have re cently en tered the mar ket, al though these still have side ef fects of dry mouth
and con sti pa tion. Takeda and Toray are con fi dent that this new drug will show ef fi cacy and side effect
advantages.
© 2009 IMS Health In cor po rated or its af fil i ates Page 73